SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (NASDAQ:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the initiation of a multi-center, multi-national Phase 2 clinical trial of Marqibo® (vincristine sulfate injection, OPTISOME™) in adult patients with relapsed acute lymphoblastic leukemia (ALL), also known as the rALLy study. Earlier this year, Marqibo was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of adult ALL.
